Tandem Diabetes Care: Solid Q4 Beat Offset by PayGo Transition Uncertainty and Competitive Headwinds Supporting Hold Rating

Danielle Antalffy, an analyst from UBS, maintained the Hold rating on Tandem Diabetes Care. The associated price target is $22.00.

Danielle Antalffy has given his Hold rating due to a combination of factors tied to both recent performance and future uncertainty. Tandem Diabetes Care delivered a solid fourth quarter, beating sales expectations with notable strength in pump shipments, better pricing, and improving profitability, particularly as pharmacy channel revenue doubled.

However, Antalffy sees the transition to the PayGo reimbursement model as introducing short‑term visibility issues, with 2026 sales guidance slightly under consensus and much of the quarter’s upside driven by lower R&D spending rather than clearly sustainable drivers. Ongoing competitive pressure in insulin pumps, questions around how durable pricing benefits will be as pharmacy access expands, and the need for clearer proof that new products and partnerships can materially improve share limit conviction to move beyond a Hold view at this stage.

In another report released today, TipRanks – PerPlexity also reiterated a Hold rating on the stock with a $19.00 price target.